Gastroparesis Treatment Market

Gastroparesis is a condition that affects the stomach muscles. It is a disease condition in which the stomach cannot empty itself of food in a normal manner. Nausea, vomiting, heartburn are the symptoms related to gastroparesis. It is most common in patients who have had diabetes for a long time and may also occur in other situations. Gastroparesis is caused due to viral infections, gastric (abdominal) surgery with injury to the vagus nerve, medications such as narcotics and some antidepressants, etc.

Market Dynamics

Strong promising pipelines developed by key players for gastroparesis treatment are anticipated to drive the gastroparesis treatment market growth. For instance, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced that the company received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A clinical trial study conducted by Processa Pharmaceuticals, Inc. for PCS12852 is in phase 2. PCS12852 is a 5-hydroxytryptamine 4 (5-HT4) receptor agonist. PCS12852 is indicated for the treatment of gastroparesis. Moreover, a surge in the number of patents for gastroparesis is likely to augment the market growth. For instance, in April 2018, EVOKE PHARMA, a specialty pharmaceutical company focused on the treatment of gastrointestinal (GI) d­­iseases, announced that the European Patent Office issued a decision to Grant European Union (EU) patent no. 2747561 for Gimoti, covering formulations of metoclopramide for the intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis, specifically for women. In addition, strategies adopted by key players such as acquisition, partnership, etc. are likely to drive the market growth. For instance, in October 2016, Allergan a pharmaceutical company acquired Motus Therapeutics, a gastrointestinal disease subsidiary of Rhythm Holding Company, following positive phase 2b trial results of Motus’ investigational treatment of diabetic gastroparesis.

Key features of the study:

• This report provides an in-depth analysis of the global gastroparesis treatment market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global gastroparesis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies.
• Key companies covered as a part of this study include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment

Detailed Segmentation:

• Global Gastroparesis Treatment Market, By Drug:
  • Metoclopramide
  • Erythromycin
  • Domperidone
  • Others
• Global Gastroparesis Treatment Market, By Type:
  • Diabetic gastroparesis
  • Idiopathic gastroparesis
  • Post-surgical gastroparesis
• Global Gastroparesis Treatment Market, By Route of Administration:
  • Intravenous
  • Nasal
  • Oral
• Global Gastroparesis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Gastroparesis Treatment Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Processa Pharmaceuticals, Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • EVOKE PHARMA
  • Neurogastrx, Inc.
  • Vanda Pharmaceuticals Inc.
  • ANI Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc.
  • Otsuka Holdings Co., Ltd.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Atlantic Healthcare
  • Salix Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.